Published data revealed that nearly 46% of B-ALL patients [5], 13% of B-cell lymphoma patients [6] treated with anti-CD19 CAR-T treatment, and 41% of MM patients treated with BCMA CAR-T [7] experience severe CRS (grade ≥ 3). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.